Table 1.

Baseline characteristics stratified by trial and treatment allocation

CharacteristicAVOIDVITALRADAR
PlaceboAliskiren (150–300 mg/d)PlaceboParicalcitol (2 µg/d)PlaceboAtrasentan (0.75 mg/d)Atrasentan (1.25 mg/d)
Participants, n2342307065476865
Age, yr61.7 (9.2)59.6 (9.6)64.7 (9.5)63.6 (10.1)64.9 (8.6)65.1 (10.10)63.7 (9.11)
Men, %75.669.166.771.480.977.966.2
eGFR, ml/min per 1.73 m266.4 (24.0)69.7 (25.1)39.9 (18.7)43.9 (18.4)48.4 (12.7)48.6 (15.00)51.5 (13.4)
Systolic BP, mmHg133.4 (11.8)134.3 (11.6)141.2 (17.1)140.3 (15.5)135.6 (12.8)138.2 (14.4)134.4 (14.1)
Diastolic BP, mmHg76.7 (8.9)77.4 (7.9)74.0 (11.0)73.7 (9.6)71.9 (10.3)74.4 (10.0)74.0 (9.5)
Hemoglobin A1C, %7.8 (1.37)8.0 (1.38)7.5 (1.24)7.6 (1.31)7.3 (1.28)7.5 (1.51)7.5 (1.34)
Hemoglobin, g/dl13.4 (1.54)13.6 (1.71)12.3 (1.72)12.2 (1.62)12.7 (1.85)12.9 (1.448)12.8 (1.86)
Total cholesterol, mg/dl177.6 (42.66)181 (41.77)166.4 (48.6)176.4 (50.2)184.1 (46.9)176.3 (39.6)173.4 (40.44)
Geometric mean UACR (IQR), mg/g755 (283–1017)733 (239–972)853 (263–1277)851 (246–1203)1143 (410–1550)1162 (530–1648)1011 (491–1381)
  • Data are presented as the mean (SD) unless otherwise indicated. UACR, urinary albumin/creatinine ratio; IQR, interquartile range; AVOID, Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy; VITAL, Selective Vitamin D Receptor Activation for Albuminuria Lowering; RADAR, Residual Albuminuria Lowering with Endothelin Antagonist Atrasentan.